Shots:

• Tetra and Targeted Pharmaceuticals collaborated with George Mason University NCBID to examine the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications
• The collaboration with Targeted provides expertise into the areas of drug development to expand the potential Return on Investment of ARDS-003
• The agreement will advance the antiviral CNS program- which is expected to grow to $163.05B in 2025

 ­ Ref: Tetra | Image: Yahoo Finance